BRPI0512651A - método para a preparação de derivados de 5-4-(2-hidroxietil)-3,5-dioxo-4,5 dihidro-3h-1,2,4-trizin-2-ila com atividade inibidora de p2x7 por reaçaõ do derivado não substituìdo na posição 4 da trizina com um oxirano na presença de um ácido de lewis - Google Patents

método para a preparação de derivados de 5-4-(2-hidroxietil)-3,5-dioxo-4,5 dihidro-3h-1,2,4-trizin-2-ila com atividade inibidora de p2x7 por reaçaõ do derivado não substituìdo na posição 4 da trizina com um oxirano na presença de um ácido de lewis

Info

Publication number
BRPI0512651A
BRPI0512651A BRPI0512651-7A BRPI0512651A BRPI0512651A BR PI0512651 A BRPI0512651 A BR PI0512651A BR PI0512651 A BRPI0512651 A BR PI0512651A BR PI0512651 A BRPI0512651 A BR PI0512651A
Authority
BR
Brazil
Prior art keywords
dioxo
hydroxy
preparing
alkyl
dihydro
Prior art date
Application number
BRPI0512651-7A
Other languages
English (en)
Inventor
Jason Albert Leonard
Zheng Jane Li
Zhengong Bryan Li
Frank John Urban
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0512651A publication Critical patent/BRPI0512651A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

MéTODO PARA A PREPARAçãO DE DERIVADOS DE 5-4- (2-HIDROXIETIL) -3,5-DIOXO-4,5-DIIDRO-3H-l,2,4-TRIAZIN-2-ILA COM ATIVIDADE INIBIDORA DE P2XY POR REAçãO DO DERIVADO NãO SUBSTITUìDO NA POSIçãO 4 DA TRIZINA COM UM OXIRANO NA PRESENçA DE UM áCIDO DE LEWIS A presente invenção se refere a métodos de preparação de compostos de fórmula (1), em que R¬ 7¬ e -CH~ 2~-C(R¬ 10¬R¬ 11¬)-OH, em que R¬10¬ e R¬ 11¬ são independentemente selecionados no grupo que consiste em hidrogênio, fenila e (C~ 1~-C~ 6~) alquila opcionalmente substituida com um a três halos, hidróxi, -CN, (C~ 1~-C~ 6~)alcóxi, ((C~1~-C~ 6~)alquil)~ n~-N-, (C~ 1~-C~ 6~) alquil- (C=O) -, (C~ 3~-C~ 8~)cicloalquil- (C=O)-, heterocicloalquil-(C=0)- de 5 ou 6 elementos, fenil-(C=O)-, naftil-(C=O)-, heteroaril-(C=O)- de 5 ou 6 elementos, (C~ 1~-C~ 6~)alquil-(C=O)O-, (C~ 1~-C~ 6~)alquil-O(C=O) -, (C~ 3~-C~ 8~)cicloalquila, fenila, naftila, heterocicloalquila de 5 ou 6 elementos e heteroarila de 5 ou 6 elementos, em que R¬ 1¬, R¬ 2¬ e R¬ 4¬ têm qualquer um dos valores definidos no relatório, em que o dito método compreende a reação de um composto de fórmula (II) com um composto de fórmula (VIII), na presença de pelo menos um ácido de Lewis. Os compostos são utilizáveis como agentes no tratamento de doenças, incluindo doenças inflamatórias, como artrite reumatóide. Também se apresentam composições de 2-cloro-N-(1-hidróxi-cicloeptilmetil) -5- ¢4- (2R-hidróxi-3-metóxi-propil) -3,5-dioxo-4,5-diidro-3H- ¢1,2,4!triazin-2-il! -benzamida cristalina compreendendo menos de 2,5% de solvente orgânico residual e métodos para a preparação das ditas composições. Além disso, apresentam-se métodos para a cristalização de 2-cloro-N- (1-hidróxi-cicloeptilmetil) -5- ¢4- (2R-hidróxi-3-metóxi-propil)-3,5-dioxo-4,5-diidro-3H-1,2,4!triazin-2-il!-b enzamida.
BRPI0512651-7A 2004-06-29 2005-06-17 método para a preparação de derivados de 5-4-(2-hidroxietil)-3,5-dioxo-4,5 dihidro-3h-1,2,4-trizin-2-ila com atividade inibidora de p2x7 por reaçaõ do derivado não substituìdo na posição 4 da trizina com um oxirano na presença de um ácido de lewis BRPI0512651A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58381304P 2004-06-29 2004-06-29
US66975605P 2005-04-08 2005-04-08
PCT/IB2005/002102 WO2006003513A1 (en) 2004-06-29 2005-06-17 Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid

Publications (1)

Publication Number Publication Date
BRPI0512651A true BRPI0512651A (pt) 2008-03-25

Family

ID=35124636

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512651-7A BRPI0512651A (pt) 2004-06-29 2005-06-17 método para a preparação de derivados de 5-4-(2-hidroxietil)-3,5-dioxo-4,5 dihidro-3h-1,2,4-trizin-2-ila com atividade inibidora de p2x7 por reaçaõ do derivado não substituìdo na posição 4 da trizina com um oxirano na presença de um ácido de lewis

Country Status (13)

Country Link
US (1) US20050288288A1 (pt)
EP (1) EP1768965A1 (pt)
JP (1) JP2008504362A (pt)
KR (1) KR20070115583A (pt)
AR (1) AR052307A1 (pt)
AU (1) AU2005258924A1 (pt)
BR (1) BRPI0512651A (pt)
CA (1) CA2572118A1 (pt)
IL (1) IL180239A0 (pt)
MX (1) MXPA06015273A (pt)
NO (1) NO20070528L (pt)
TW (1) TW200612965A (pt)
WO (1) WO2006003513A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
BRPI0410349A (pt) 2003-05-12 2006-05-30 Pfizer Prod Inc inibidores de benzamida do receptor p2x7
WO2008142194A1 (es) 2007-05-17 2008-11-27 Universidad Complutense De Madrid Método de diagnóstico / pronóstico in vitro de la corea de huntington
MX2010004705A (es) * 2007-10-31 2010-05-27 Nissan Chemical Ind Ltd Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
PL2105164T3 (pl) 2008-03-25 2011-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści P2X7R i ich zastosowanie
PL2243772T3 (pl) 2009-04-14 2012-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści p2x7r i ich zastosowanie
WO2011141194A1 (en) 2010-05-14 2011-11-17 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
BR112017022654A2 (pt) 2015-04-24 2018-07-10 Shionogi & Co., Ltd. derivado heterocíclico de 6 membros e composição farmacêutica compreendendo o mesmo
KR102528627B1 (ko) 2016-10-17 2023-05-03 시오노기 앤드 컴파니, 리미티드 2환성 함질소 헤테로환 유도체 및 그를 함유하는 의약 조성물

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US40513A (en) * 1863-11-03 Improved folding table
US32807A (en) * 1861-07-09 Improvement in harvesters
US186981A (en) * 1877-02-06 Improvement in cotton-cleaners
US72876A (en) * 1867-12-31 margin
US13704A (en) * 1855-10-23 Melodeobt
US180894A (en) * 1876-08-08 Improvement in mortise-latches
US13721A (en) * 1855-10-30 Peter hogg
US9900A (en) * 1853-08-02 Improvement in temples for looms
US4318731A (en) * 1979-08-25 1982-03-09 Nihon Nohyaku Co., Ltd. Δ2 -1,2,4-triazolin-5-one derivatives and herbicidal usage thereof
AU542544B2 (en) * 1980-03-12 1985-02-28 Nippon Kayaku Kabushiki Kaisha Tetrahydrophthalimide derivatives
AU578708B2 (en) * 1984-06-12 1988-11-03 Fmc Corporation Herbicidal 2-aryl-1,2,4-triazine-3,5(2h,4h)-diones and sulfuranalogs thereof
US4766233A (en) * 1984-06-12 1988-08-23 Fmc Corporation Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof
US4806145A (en) * 1984-10-31 1989-02-21 Fmc Corporation Herbicidal aryl triazolinones
JPS6299368A (ja) * 1985-10-26 1987-05-08 Nippon Nohyaku Co Ltd Δ↑２−１，２，４−トリアゾリン−５−オン誘導体及びその製法並びにその用途
EP0333791A1 (de) * 1987-09-23 1989-09-27 Ciba-Geigy Ag Heterocyclische verbindungen
US5411980A (en) * 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
WO1992020662A1 (en) * 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5686061A (en) * 1994-04-11 1997-11-11 The Board Of Regents Of The University Of Texas System Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors
US6147101A (en) * 1995-06-02 2000-11-14 Kyorin Pharmaceutical Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6001862A (en) * 1995-06-02 1999-12-14 Kyorin Pharameuticals Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
JP2000506538A (ja) * 1996-03-29 2000-05-30 ジー．ディー．サール アンド カンパニー メタ―置換フェニレン誘導体
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
DE19701287A1 (de) * 1997-01-16 1998-07-23 Wernicke & Co Gmbh Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben
WO1998042669A1 (en) * 1997-03-25 1998-10-01 Astra Pharmaceuticals Ltd. Novel pyridine derivatives and pharmaceutical compositions containing them
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9704272D0 (sv) * 1997-11-21 1997-11-21 Astra Pharma Prod Novel Compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11318492A (ja) * 1998-03-09 1999-11-24 Aisin Seiki Co Ltd 蛍光発生性基質を含有する組成物
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
NZ514477A (en) * 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
US6458952B1 (en) * 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
SE9901875D0 (sv) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
IL148464A0 (en) * 2000-05-04 2002-09-12 Basf Ag Uracil substituted phenyl sulfamoyl carboxamides
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.

Also Published As

Publication number Publication date
AR052307A1 (es) 2007-03-14
JP2008504362A (ja) 2008-02-14
KR20070115583A (ko) 2007-12-06
TW200612965A (en) 2006-05-01
MXPA06015273A (es) 2007-03-15
IL180239A0 (en) 2007-07-04
NO20070528L (no) 2007-03-29
AU2005258924A1 (en) 2006-01-12
EP1768965A1 (en) 2007-04-04
US20050288288A1 (en) 2005-12-29
CA2572118A1 (en) 2006-01-12
WO2006003513A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
BRPI0512651A (pt) método para a preparação de derivados de 5-4-(2-hidroxietil)-3,5-dioxo-4,5 dihidro-3h-1,2,4-trizin-2-ila com atividade inibidora de p2x7 por reaçaõ do derivado não substituìdo na posição 4 da trizina com um oxirano na presença de um ácido de lewis
Park et al. Design, synthesis and evaluation of novel 2, 5, 6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents
NO20065578L (no) Substituerte metylaryl eller heteroarylamidforbindelser
BRPI0510963A (pt) derivados pirimidina para o tratamento do crescimento anormal de células
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
ECSP099269A (es) Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble
CY1111185T1 (el) Ανθρανιλαμιδια, μεθοδος για την παρασκευη αυτων και παραγοντες ελεγχου επιβλαβων εντομων που τα περιεχουν
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
DK1740584T3 (da) Kondenseret chinolinderivat og anvendelse deraf
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
DK1618092T3 (da) Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
BRPI0510980A (pt) derivados de pirimidina para o tratamento do crescimento anormal de células
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
BRPI0607589A2 (pt) derivados de imidazo [1,5-a] piridinas, o respectivo processo de preparo e as composições farmacêuticas que os contêm
BRPI0517455A (pt) compostos orgánicos
DK1961734T3 (da) Aminforbindelse og anvendelse deraf til medicinske formål
NO20090233L (no) Ny sammensetning som har affinitet for amyloid
WO2007081690A3 (en) Inhibitors of protein kinases
Dixit et al. Synthesis of novel benzimidazole derivatives: as potent analgesic agent
Felicetti et al. Studies on 2-phenylquinoline Staphylococcus aureus NorA efflux pump inhibitors: New insights on the C-6 position
BRPI0409049A (pt) métodos de preparação de um composto, composição e composição cristalina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.